Tags : Hemophilia


Takeda Collaborates with Enzyre to Develop Diagnostic Device to Regulate

Shots: Enzyre to receive funding to advance its existing technology for the development of the diagnostic device, allowing hemophilia patients to automatically determine their coagulation status at home and transfer test results to HCPs via app The focus of the collaboration is to deliver patient-centric, personalized healthcare to patients and to advance SOC of patients […]Read More


Sanofi to Acquire Bioverativ to Treat Hemophilia

Shots: Sanofi acquires Bioverativ, in all stock transaction with its Eloctate & Alprolix products. Bioverativ to receive $105/share in cash for a premium of 64 % with total deal value as $11.6B The focus of the agreement is to combine Bioverativ’s expertise with its platform for the advancement of fitusiran to treat Hemophilia A and […]Read More